ArticleExperimental eye research2019
Menopause exacerbates visual dysfunction in experimental glaucoma.
Article in Experimental eye research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 31 citations in OpenAlex.
- Mouse predation is dependent on a population of POU6F2-positive retinal ganglion cells.iScience · 2026Article
- Soluble guanylate cyclase deficiency drives retinal ganglion cell neurodegeneration with age in female mice through disrupted oxidative metabolism.Scientific reports · 2026Article
- Effect of estrogen and progesterone therapy on intraocular pressure: a systematic review and meta-analysis study.European journal of translational myology · 2025Article
- Retina-Targeted 17β-Estradiol by the DHED Prodrug Rescues Visual Function and Actuates Neuroprotective Protein Networks After Optic Nerve Crush in a Rat Model of Surgical Menopause.International journal of molecular sciences · 2025Article
- RetOCTNet: Deep Learning-Based Segmentation of OCT Images Following Retinal Ganglion Cell Injury.Translational vision science & technology · 2025Article
- Testing Visual Function by Assessment of the Optomotor Reflex in Glaucoma.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Ovariectomy drives increase of an ECM transcription signature in the posterior eye and retina.Vision research · 2024Article
- Navigating Surgical Challenges: Managing Juvenile Glaucoma in a Patient with Dorfman-Chanarin Syndrome.Biomedicines · 2024Article
- Postmenopausal Hormone Therapy Was Associated With Later Age of Onset Among Glaucoma Cases.Investigative ophthalmology & visual science · 2024Article
- Association of Age of Menopause and Glaucoma Diagnosis in Female Veterans.Investigative ophthalmology & visual science · 2024Article
- Estrogen dysregulation, intraocular pressure, and glaucoma risk.Experimental eye research · 2023Review
- CREG Protects Retinal Ganglion Cells loss and Retinal Function Impairment Against ischemia-reperfusion Injury in mice via Akt Signaling Pathway.Molecular neurobiology · 2023Article
- Evidence for Menopause as a Sex-Specific Risk Factor for Glaucoma.Cellular and molecular neurobiology · 2023Review
- Article
- Evaluation of Spatially Targeted Scleral Stiffening on Neuroprotection in a Rat Model of Glaucoma.Translational vision science & technology · 2022Article
- Sex Hormones and Their Effects on Ocular Disorders and Pathophysiology: Current Aspects and Our Experience.International journal of molecular sciences · 2022Review
- Girl Power in Glaucoma: The Role of Estrogen in Primary Open Angle Glaucoma.Cellular and molecular neurobiology · 2022Review
- Diabetic neovascularization defects in the retina are improved by genistein supplementation in the ovariectomized rat.Inflammopharmacology · 2021Article
- Proteomics-Based Retinal Target Engagement Analysis and Retina-Targeted Delivery of 17β-Estradiol by the DHED Prodrug for Ocular Neurotherapy in Males.Pharmaceutics · 2021Article
- Ovariectomy worsens visual function after mild optic nerve crush in rodents.Experimental eye research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Glaucoma is the leading cause of irreversible blindness worldwide. Recently, estrogen deficiencies caused by early menopause, alterations in estrogen signaling via mutations in estrogen receptors, and polymorphisms along estrogen metabolic pathways have all been linked to an increased risk of developing glaucoma. Here, we examined how menopause and age impact visual function and retinal structure in an experimental model of glaucoma. Young (3-4 months) and aged (9-10 months) female Brown Norway rats were divided into pre- and post-menopausal cohorts by surgically inducing menopause via ovariectomy (OVX). After six weeks, ocular hypertension (OHT) was induced unilaterally for a period of eight weeks. Four cohorts were successfully followed to eight weeks: young sham (n = 8), young OVX (n = 9), aged sham (n = 10), and aged OVX (n = 11) animals. Intraocular pressure (IOP) was monitored weekly in all groups. Prior to inducing OHT (baseline) and at four and eight weeks after inducing OHT, we assessed visual acuity via the optomotor response (OMR) and retinal structure using optical coherence tomography (OCT). OHT decreased the OMR in all cohorts. We found that spatial frequency thresholds decreased by 54% in OVX animals after OHT compared to sham animals after OHT, regardless of age (p < 0.001). We also found thinning of the retinal nerve fiber layer (RNFL) and loss of total retinal thickness after induction of OHT. Aged animals had more thinning of the RNFL and loss of total retinal thickness compared to young animals (p < 0.001). Overall, OHT caused significant changes in visual function and retinal structure. Observing that OVX in young and aged animals further decreased spatial frequency thresholds after OHT suggests that an estrogen deficiency may intensify visual impairment after OHT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.